Présentation de l'entreprise
SCWorx Corp. operates within the healthcare sector, specifically functioning in the health information services industry by providing data content and specialized services focused on the repair, normalization, and interoperability of information for healthcare providers in the United States. The company develops and markets healthcare information technology solutions along with associated services to facilitate better data management within the medical sector. This enterprise currently maintains a market capitalization of $1.89M and reports annual revenue of $2.88M over the trailing twelve-month period. With an employee count listed as N/A, the company's specific operational scale remains undefined in terms of workforce size, though its financial metrics indicate a small-cap positioning. The relatively modest market capitalization of $1.89M, combined with annual revenue of $2.88M, suggests that SCWorx Corp. occupies a niche position in the broader healthcare technology landscape rather than dominating a significant portion of the market.
Santé financière
SCWorx Corp. reported a revenue of $2.88M for the trailing twelve months, yet the net income stands at a significant loss of $-4,444,109, while the EBITDA figure is $-958,315. The substantial gap between the positive revenue of $2.88M and the negative net income of $-4,444,109 reveals a cost structure where operating expenses and taxes far exceed gross profits, indicating high burn rates relative to sales. The free cash flow is recorded at $-814,822, which indicates that the company is consuming cash to fund its operations and growth initiatives rather than generating surplus liquidity for distribution or debt repayment. Analyzing the margins shows a gross margin of 32.0%, suggesting that the company retains nearly one-third of revenue after direct costs, but this is insufficient to cover overheads given the operating margin of -25.0%. The profit margin is even more distressed at -154.4%, highlighting that for every dollar of sales, the company loses more than a dollar in net earnings. On the balance sheet, the company holds $1.64M in cash against $151,377 in debt, resulting in a debt-to-equity ratio of 2.12, which implies a leveraged capital structure where equity is less than double the debt burden. Despite the high leverage, the current ratio of 2.72 indicates strong short-term liquidity, as current assets are significantly higher than current liabilities, providing a buffer for immediate obligations. Return on Equity is -76.3% and Return on Assets is -8.4%, metrics that collectively reveal that management effectiveness is currently negative, as the company is destroying shareholder value and utilizing assets inefficiently to generate profit.
Évaluation de la valorisation
The trailing P/E ratio is N/A and the forward P/E is also N/A due to the company's lack of positive earnings, implying that traditional earnings-based valuation multiples are inapplicable at this stage of the firm's financial lifecycle. The price-to-book ratio stands at 0.23, indicating that the market values the company at roughly 23% of its book value, which suggests a significant discount relative to the underlying net asset value often seen in distressed or unprofitable small-cap stocks. The price-to-sales ratio is 0.66, while the EV/EBITDA is -0.42; these alternative valuation metrics suggest that the company is being valued based on revenue generation and enterprise value adjustments rather than profitability, as the negative EV/EBITDA reflects the net negative earnings before interest, taxes, depreciation, and amortization. The stock has traded between a 52-week high of $1.37 and a 52-week low of $0.11, and without a specific current price provided in the source data, the valuation range establishes a wide band of volatility within which the share price fluctuates. The beta value is 2.26, which means the stock is expected to be highly volatile and will likely move with significantly greater magnitude than the broader market index during periods of equity market turbulence.
Growth & Income
SCWorx Corp. has demonstrated a revenue growth of 13.8% year-over-year, whereas the earnings growth is N/A due to the company's persistent losses, implying that top-line expansion has not yet translated into bottom-line profitability. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, indicating that the firm retains all earnings—or in this case, all losses—to reinvest into its operations or to service its existing debt obligations rather than distributing cash to shareholders. The absence of a dividend yield confirms that the company prioritizes capital allocation toward internal growth initiatives, R&D, or operational stabilization over shareholder income distribution. Overall, the growth and income profile for SCWorx Corp. is characterized by accelerating revenue growth coupled with substantial negative earnings and a lack of dividend income, presenting a high-risk, high-volatility investment characteristic typical of early-stage biotech or health-tech firms seeking profitability.